Hormone Health Data and Research Act
- Bill Number
- H.R. 9077
- Origin Chamber
- House
- Congress
- 119th Congress, Session 2
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2026-05-29: Referred to the House Committee on Energy and Commerce.
- Last Updated
- 2026-06-24T18:03:51Z
AI-Generated Summary
Purpose This legislation directs federal health agencies to review existing evidence on hormone levels in women prior to perimenopause symptoms. Its goal is to assess variability patterns and the usefulness of hormone testing for diagnosis and management of perimenopause.
Key Provisions
- The Director of the National Institutes of Health (NIH) must evaluate published evidence on hormone variability in women before perimenopause symptoms appear and identify any baseline patterns.
- The Secretary of Health and Human Services, through the U.S. Preventive Services Task Force (USPSTF), must review evidence on whether hormone testing provides baseline information that meaningfully aids perimenopause diagnosis or management.
- Both agencies must jointly submit a report within 18 months of enactment to the House and Senate Appropriations Committees, the House Energy and Commerce Committee, and the Senate Health, Education, Labor, and Pensions Committee. The report must summarize findings, note evidence gaps, and offer recommendations for future research or clinical guidance.
Significant Changes to Existing Law The bill introduces new mandatory reviews of prior research by NIH and USPSTF but does not amend or repeal any existing statutes. It adds targeted research directives focused on perimenopause without altering current agency authorities or funding structures.
Potential Impacts
- Government agencies: Requires NIH and USPSTF to allocate resources for evidence reviews and report preparation, potentially influencing future research priorities.
- Citizens: Could lead to improved clinical understanding of perimenopause if gaps are identified, though no direct changes to patient care or testing standards are mandated.
- International relations: No provisions affect foreign policy or international agreements.
Main Stakeholders Affected
- Women approaching or experiencing perimenopause.
- NIH and USPSTF as the primary agencies conducting the reviews.
- Congressional committees receiving the report.
- Health care providers and researchers who may use the findings for future guidance.
Notable Legal, Constitutional, or Political Implications The bill raises no apparent constitutional issues, as it falls within Congress's authority to direct federal research. It carries no legal mandates for new regulations or testing requirements and focuses solely on evidence evaluation without political or partisan directives in the text.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Rep. Scholten, Hillary J. [D-MI-3]
Recent Actions
- 2026-05-29: Referred to the House Committee on Energy and Commerce.
- 2026-05-29: Introduced in House
- 2026-05-29: Introduced in House
Bill Versions
- Hormone Health Data and Research Act — issued 2026-05-29 — PDF (3 pages)